Toragen, Inc.

Who We Are

Where We're Going

What We're Doing

Our team is comprised of industry leaders with decades of experience in early-stage biotechnology companies, translational drug development, and pivotal clinical trials.

Meet the Team

What We're Doing

Where We're Going

What We're Doing

Toragen is focused on developing novel cancer treatments to treat viral-associated cancers and significant infections.

Learn More

Where We're Going

Toragen completed a Phase I clinical trial with its lead compound in HPV-induced cancer.

See What's in Store

Our Technology

Market Opportunity in HPV-Induced Cancers

Toragen, Inc. is a clinical-stage oncology company focusing on the treatment of Human Papillomavirus (HPV) induced cancers, which cause 5% of all cancers worldwide.

Head and neck cancer (OPSCC) is a significant worldwide health issue with high mortality and morbidity. Despite an approved vaccine against HPV, incidences of HPV-induced cancers continue to rise and are expected to nearly double by 2040.

About 70,000 new cases of OPSCC are predicted to occur each year, resulting in 34,000 deaths.

Despite advances in therapy over the past decade, there remains significant morbidity and mortality from this disease. There is clearly an urgent need to develop effective new treatment options for patients with OPSCC.

Anti-PD-1/PD-L1 Immunotherapy

Checkpoint Blockade Immunotherapy is revolutionizing oncology, with an estimated $30B market. Anti-PD-1/PD-L1 immunotherapy is now FDA approved to treat patients with recurrent or metastatic OPSCC with disease progression on or after platinum-containing chemotherapy. However, objective response rates to anti-PD-1 immunotherapy in HPV-induced cancers are typically below 25%. Thus there is a critical need to understand mechanisms of resistance and develop combination therapies to improve response rates.

Developing novel cancer treatments targeting oncogenic viruses

Who We Are

Where We're Going

What We're Doing

What We're Doing

Where We're Going

What We're Doing

Where We're Going

Where We're Going

Where We're Going

Our Technology

Market Opportunity in HPV-Induced Cancers

Novel Drug Development

Anti-PD-1/PD-L1 Immunotherapy

Our Pipeline

TGN-S15 Binds the HPV E5 Protein Reversing E5's Inhibition of Trafficking MHC to the Cell Surface

An open-label, non-randomized, Phase I, Dose Escalation/Dose Expansion study in cohorts of patients

Developing novel cancer treatments targeting oncogenic viruses

Who We Are

Where We're Going

What We're Doing

What We're Doing

Where We're Going

What We're Doing

Where We're Going

Where We're Going

Where We're Going

Our Technology

Market Opportunity in HPV-Induced Cancers

Novel Drug Development

Anti-PD-1/PD-L1 Immunotherapy

Our Pipeline

TGN-S15 Binds the HPV E5 Protein Reversing E5's Inhibition of Trafficking MHC to the Cell Surface

An open-label, non-randomized, Phase I, Dose Escalation/Dose Expansion study in cohorts of patients

This website uses cookies.